Approximately 70% of ovarian cancer patients have aberrations in the PI3K/AKT signaling pathway, and mutations in the gene encoding the catalytic subunit PIK3CA occur in 6–12% of patients [224, 225]. The gene discussed is AKT1; the disease is ovarian cancer.